Severe paradoxical disease activation following alemtuzumab treatment for multiple sclerosis
Open Access
- 3 September 2020
- journal article
- editorial
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology Neuroimmunology & Neuroinflammation
Abstract
A 39-year-old right-handed agricultural service engineer developed rapidly evolving severe relapsing-remitting multiple sclerosis (MS). MRI showed multiple T2 hyperintensities throughout his neuroaxis (figure, A). Several lesions showed restricted diffusion, and 2 enhanced. He received steroids for each relapse, making a full recovery (Expanded Disability Status Score [EDSS] 0).Keywords
This publication has 5 references indexed in Scilit:
- Activation of disease during therapy with alemtuzumab in 3 patients with multiple sclerosisNeurology, 2018
- Diet quality is associated with disability and symptom severity in multiple sclerosisNeurology, 2018
- An observational study of alemtuzumab following fingolimod for multiple sclerosisNeurology Neuroimmunology & Neuroinflammation, 2017
- Severe B-cell-mediated CNS disease secondary to alemtuzumab therapyThe Lancet Neurology, 2017
- Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferationProceedings of the National Academy of Sciences of the United States of America, 2013